Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAST-MDR
NCT07486024Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2026
- Primary completion
- Aug 2030
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of bedaquiline, pretomanid, linezolid, moxifloxacin in multidrug-resistant tuberculosis (MDR-TB), sponsored by Assistance publique - Hôpitaux de Paris. Started Sep 2026; status: recruiting.
02
Drugs
bedaquilinepretomanidlinezolidmoxifloxacin
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on NCT07486024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07486024.